Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx’ ANDA Approvals On Hold Pending Resolution Of Manufacturing Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”
Advertisement

Related Content

Watson Integration Of Andrx Underway With 66 Combined ANDAs Pending
Andrx’ Declining Revenue Reflects Cost Of Investments
Andrx’ Declining Revenue Reflects Cost Of Investments
Andrx Divests Oral Contraceptive ANDAs To Teva
Andrx Divests Oral Contraceptive ANDAs To Teva
Watson Acquires Andrx Despite OAI Hold Status
Amaryl Generics Hit The Market, Led By Prasco's "Authorized" Product
Andrx' Concerta Generic Likely Blocked By Another ANDA Filer's Exclusivity
Andrx' Concerta Generic Likely Blocked By Another ANDA Filer's Exclusivity
FDA Accepts Andrx’ Corrective Action Plan On Manufacturing Issues

Topics

Advertisement
UsernamePublicRestriction

Register

PS062982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel